Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRL1068 in Acute Exacerbation of Chronic Rhinosinusitis
NCT05355207Phase 1Unknown
- Sponsor
- Trellis Bioscience
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of calpurbatug in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Trellis Bioscience. Primary endpoints: Incidence of abnormal physical exam findings at 6 weeks, Incidence of abnormal serum chemistries and hematology at 6 weeks and 10 more. Status: unknown.
02
Drugs
calpurbatug
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05355207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355207.